Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors

ConclusionsThe Invitae Personalized Cancer Monitoring assay, featuring a flexible patient-specific panel design with 18 –50 variants, demonstrated high sensitivity and specificity for detecting ctDNA at variant allele frequencies as low as 0.008%. This assay may support patient prognostic stratification, provide real-time data on therapy responses, and enable early detection of residual/recurrent disease.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research